News

Pharma’s Almanac | Enabling Pharma Researchers to Think Differently with Effective Data Manipulation

Pharma researchers are tasked with organizing disparate data, which detracts from time spent understanding disease mechanisms and enabling the development of more effective drugs. Paradigm4 is tackling this issue with a new platform based on a novel approach to data organization and elastic computing. Even companies with small budgets can access this amazing computational power at a very cost-effective price. — Marilyn Matz and Zach Pitluk, Ph.D.

whitepages icon x

BioPharma Trend: A new way to work with data in life sciences

Interview with Marilyn Matz, CEO and Co-founder at Paradigm4, and 2020 NACD Directorship 100™ honoree, and her colleague Dr. Zachary Pitluk, VP of Life Sciences and Health Care at Paradigm4. Founded by renowned database researcher, Turing Award laureate MIT Professor Michael Stonebraker, Paradigm4 is not just any data analytics company

whitepages icon x

Foundational partnership with Paradigm4 enables Alnylam Pharmaceuticals to rapidly accelerate RNAi- based drug target discovery

25th October 2022: Paradigm4’s REVEAL Integrative Analytics platform enables Alnylam Pharmaceuticals to discover novel, genetically-validated drug targets from population scale biobank genotype-phenotype datasets and underlies the extraordinary pace and productivity of Alnylam’s RNAi therapeutics pipeline. Using Paradigm4’s cloud-based scientific analytics platform and data from the UK Biobank, Alnylam has identified

whitepages icon x

Technology Networks | How Can Data Platforms Unlock the Power of Single-Cell Analysis?

Single-cell technologies have positioned themselves at the forefront of biomedical research. These platforms allow researchers to bypass the uncertainties of bulk data and instead interrogate biological systems at a level of detail that was previously unreachable. by Ruairi J MacKenzie